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Abstract 
Medical researchers and biologists have long been fascinated by the possibility of changing the identity of cells, a 
phenomenon known as cellular plasticity. Now, we know that differentiated cells can be experimentally coaxed to 
become pluripotent (cellular reprogramming). Recent studies have demonstrated that changes in cell identity are 
not limited to the laboratory, but also the tissue cells in live organisms are subjected to this process, too 
(endogenous cellular reprograming). Nowadays “reprogramming technology” has created new opportunities in 
understanding human chronic diseases, drug discovery, and regenerative medicine. This technology have enabled 
the generation of various specific cell types including cardiomyocytes, pancreatic beta cell, and neurons, from 
patient’s cells such as skin fibroblasts. Reprogramming technology provides a novel cell source for autologous cell 
transplantation. But, cell transplantation faces several difficult hurdles such as cell production and purification, 
long-term survival, and functional integration after transplantation. Recently, in vivo reprogramming, which uses 
endogenous cells for tissue repair, has emerged as a new approach to circumvent cell transplantation. Up till now, 
in vivo reprogramming has been practiced in the mouse pancreas, heart, brain, and spinal cord with various 
degrees of success. In this review, we summarize the progress made, therapeutic potentials, and the challenges 
ahead in this emerging research area. 
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Introduction1 
The ability to modify and return a cell to pre-
differentiation conditions is a new concept in 
biology and medicine research. This concept 
was first taken into account in cloning studies 
conducted by Gurdon et al. on Xenopus laevis1 
and later by Campbell et al. conducted on 
sheep.2 
In these studies, unknown factors found in 
the cytoplasm of the oocyte cell were used to 
convert somatic cells to near-embryonic ones; 
the cells formed eventually became viable 
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organisms. In 2006, Takahashi and Yamanaka 
realized that by applying a combination of 
several transcription factors to somatic cells, 
they could be returned to pluripotent state. 
This cells are structurally and functionally 
close to the fetal state. These cells were called 
induced pluripotent stem cells.3 
Takahashi et al. revealed the molecular 
basis of cloning, and it became clear that when 
the nucleus of a cell is inserted into the oocyte 
cell, it actually puts the nucleus in an 
environment that contains transcription factors 
and, more generally, in the same intracellular 
conditions as the fetal state. In this condition, 
the genetic material inside the nucleus is 
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reprogrammed and the resulting cell can create 
a complete organism.4 Using this method, 
Yamanaka reprogrammed skin fibroblasts into 
inducible stem cells and provided a solid basis 
for the production of other body cells.5  
Of course, it is worth noting that in other 
studies carried out in the following years, 
researchers observed that using just one 
transcription factor, cells evolutionary closely 
together, such as fibroblasts and muscle cells, 
as well as B-lymphocytes and macrophages, 
can be converted to each other.6,7 But, the 
importance of the researches by Yamanaka, 
Takahashi, and their colleagues was to 
reprogram the cells to a more fundamental 
state that would allow researchers to produce 
a wide range of cells.3-5 In the following years, 
studies showed it possible that cells such as 
neurons be produced from skin fibroblasts, 
directly and without passing through the 
stemness stage.8-10 This approach of converting 
cells is called as “transdifferentiation”. This 
conversion method was examined both in the 
culture medium and in animal models, and 
achieved acceptable results.11-19 Altogether, a 
new research field named “cellular 
reprogramming” and “in vivo reprogramming”, 
which is one of the most powerful branches of 
cell reprogramming, has been founded.  
Recently, in vivo reprogramming has 
attracted the attention of many researchers 
worldwide.20 The importance of this method 
lies in its high potentials for clinical application 
and medical use. In fact, this method of 
treatment was actually found in response to 
this question: "Can tissues or cells inside the 
body be converted directly to another ones?"  
One of the first studies on this area was 
performed on pancreatic cells. Since these cells 
were flexible enough in transforming into 
developmentally close cells.12 In the next step, 
the method was also tested on cardiac and 
neural tissues. These experiments showed that 
it was possible to transform the cardiac and 
neuronal cells by applying a cocktail of 
transcription factors.13-16 In the present review, 
we discuss the advantages of the traditional 
method of cell therapy and in vivo 
reprogramming method, as well as examples 
of researches done in the chronic diseases field 
of study. Finally, we discuss the therapeutic 
potentials of this method and also the 
challenges ahead. 
Traditional cell therapy techniques 
Years ago, when reprogramming technology 
had not existed, cell therapy approach was 
carried out at university laboratories or even in 
the clinic. In these researches and clinical trials, 
pluripotent stem cells such as embryonic 
cells,21 or multipotent ones such as bone 
marrow cells, were transplanted to patients 
suffering chronic diseases.22,23 These studies 
have been well considered by Kim and de 
Vellis for neurological diseases,24 Segers and 
Lee for heart tissue repair,25 Fadini et al. for 
vascular diseases,26 and Branski et al. for 
wound healing,27 in their reviews. Despite all 
the valuable efforts of outstanding researchers 
in this field of study, traditional therapies with 
their limitations have illuminated the need for 
a new method to overcome these barriers.  
In vivo reprogramming as a novel 
therapeutic approach 
So far, most of the works related to the 
replacement of deaths cell due to diseases have 
been concentrated on cell transplantation; but 
there are lots of limitations in cell 
transplantation. First of all that stem cells 
transplanted to the site of injury are not viable, 
and in most cases they die. Second, these cells 
stimulate the immune response, and are 
destroyed by the immune system before being 
able to differentiate to the required at the site 
of damage.28-30 
To solve this problem, in vivo 
reprogramming method can be used; it means 
that instead of producing stem cells in the 
culture medium, and then transplanting them 
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into the area of injury, cells that are found at 
the site of the injury can be converted to the 
desired ones to repair the damaged tissue. In 
this method, using viral vectors, transcription 
factors could be targeted to special cells in the 
area and convert them to another type of cell 
that is needed. Another limitation of 
traditional cell transplantation method is the 
complexity of the process of differentiating 
cells into desired cells. As we know, the niche 
around the cells of a tissue, contains growth 
factors and chemical messengers that provide 
an exclusive environment to minimizes the 
probability of unwanted cell production in the 
area.31 Therefore, we can take advantage of this 
exclusive condition by performing a process of 
reprogramming inside the body and tissue. 
This article focuses on the history of in-vivo 
reprogramming in chronic diseases and its 
progress up to now. Since studies in this field 
have been conducted mostly on chronic 
diseases including pancreatic, heart and 
nervous tissue damages, in the present article, 
we review the articles on in vivo 
reprogramming with emphasis on in these 
three tissues. 
In vivo reprogramming in pancreatic 
cells 
The first attempts to transform cells in vivo to 
produce beta cells from other cells in the 
pancreas was carried out in 2008 by Zhou et 
al.12 In their study, the transcription factors 
that had specifically expressed in beta cells of 
the pancreas were injected into the pancreas, 
and the conversion of exocrine cells of this 
tissue into beta cells were examined. The 
researchers eventually introduced 
synchronous injection of three Ngn3, Pdx1, 
and Mafa transcription factors as the most 
efficient way to make this conversion. In their 
research, reprogramming was carried out 
directly, meaning that the extracellular cells 
were transformed into beta cells without 
passing through the embryonic stages 
(pluri/multipotent stages). These beta cells 
were active (insulin and growth factors were 
secreted). Interestingly, by applying the same 
factors in the culture medium, the cellular 
transformation observed in vivo, was not 
observed, probably due to the absence of in 
vivo agents in culture medium.12  
Following the success of Zhou et al. project, 
further studies were done in this field. They 
showed that cells that do not secret insulin can 
be reprogrammed into insulin secreting beta 
cells by using transcriptional factors and 
cytokines.32-34 Despite the successful results, 
effectiveness of this method in mice was 
relatively low, which, according to a recent 
study, can be referred to hyperglycemia and its 
inhibitory effect on reprogramming of exocrine 
cells.35. It has also been shown in several 
studies that pancreatic cells have an intrinsic 
ability and flexibility of converting to each 
other.36 For example, in a study by Thorel  
et al.,37 it was observed that even when 
diphtheria toxin was continuously injected into 
mice in toxic doses for beta cells, insulin 
production continued, and mice survived. By 
tracking the source of beta cells, they found 
that these cells derived from alpha cells of the 
same tissue. A remarkable point in this study 
was that they used any transcription factor, 
and concluded the intrinsic flexibility of 
pancreatic cells as the main reason for this 
phenomena.37 The question that now arises is: 
“Are the cells of other tissues also able to do this, 
or it is an exclusive feature of pancreatic cells?”  
On the way to answer this question, further 
steps were taken in the development of in-vivo 
reprogramming. So, the next step was to look 
at the conversion of cells that were 
developmentally close to pancreatic cells. The 
liver cells were selected to answer this 
question. They tried to convert these cells via 
the three above-mentioned transcription 
factors. Surprisingly, the conversion has 
occurred and some duct structures that 
expressed beta cell markers were developed in 
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the liver. This newly produced cells eliminated 
the symptoms in animal models diabetes.38 
Another study by Ariyachet et al. also found 
that intestinal cells could be converted to insulin-
secreting cells.39 These results led the researchers 
to conclude that the evolutionary close tissues 
had a potential for in-vivo reprogram to each 
other. All this together encouraged these 
scientists to continue their path. 
The efforts of researchers in this field to date 
have focused on finding more efficient methods 
to convert different somatic cells into beta cells. 
For example, some researchers are focused on 
finding more efficient cocktail of transcription 
factors, while others have been working with 
creative methods to find other ways to 
reprogram these cells without expression of 
transcription factors.40,41 It is worth noting that 
these researcher’s efforts for reprograming 
mesoderm cells continued, and recently 
Rezvani et al.42 and also Song et al.43 have 
shown that myofibroblasts can be converted 
into hepatocytes to treat hepatic fibrosis. 
In vivo reprogramming in cardiac tissue 
As discussed in the previous section, one of the 
challenges facing in vivo reprogramming is the 
conversion of evolutionary distant cells. In 
contrast to the pancreas, in cardiac tissue, 
fibroblast cells and cardiomyocytes come from 
different progenitors, but the source of both of 
them is the mesodermal embryonic layer; the 
advantage of in-vivo reprogramming in the 
cardiac tissue is the presence of abundant 
sources of cardiac fibroblasts which migrate to 
the lesion area after heart damage. This feature 
led the researchers to test this hypothesis 
whether cardiac fibroblasts could be converted 
to cardiomyocytes at the site of the damage?  
In 2009, Takeuchi and Bruneau designed an 
experiment to respond to this question. They 
reprogrammed embryonic mesoderm tissue 
into cardiac tissue using transcription factors 
GATA4, Tbx5, and Baf60c.44 In 2012, Inagawa 
et al. observed that non-myocyte cells could be 
converted to induce cardiomyocytes by 
applying a cocktail of transcription factors 
including Gata4, Mef2c, and Tbx5 (GMT).45 
Interestingly, when this process was done in 
vivo, is was more efficient than in vitro, and also 
the transcriptome of converted cells was very 
similar to cardiomyocytes. On the other hand, 
these cells were also active electrophysiologicaly 
similar to cardiomyocytes.13,46  
After this study, other studies were also 
carried out to increase the efficiency of the 
GMT cocktail.47 As an example, the addition of 
Hand2 transcription factor to GMT (GHMT) 
improved the efficiency of reprogramming, 
and improved cardiac activity. GHMT also 
produced various heart cells, including 
ventricle, atrium, and conductive tissue.48,49 
Then, other studies using the same method on 
rat's heart were performed with different sets 
of transcription factors.50-53 By introducing 
miRNAs and their widespread use in cell 
reprogramming, after much effort, in 2015, 
Jayawardena et al. demonstrated that miRNAs 
also could play an important role in cardiac 
cells reprogramming.54 In vivo reprogramming 
itself led to angiogenesis and increased blood 
flow to newly converted cells, but it was not 
enough. Therefore, the researchers used 
angiogenesis stimulator, and they were 
surprised to find that these stimuli 
significantly increased the efficiency of in-vivo 
reprogramming.13 Mathison  et al. showed that 
another factor that influenced angiogenesis, 
the vascular endothelial growth factor, also 
had a positive impact on the efficiency of GMT 
on in-vivo reprogramming.55 
One of the major problems in heart stroke is 
fibrosis, which is caused by fibroblast 
secretions. In studies of cardiac in vivo 
reprogramming, cardiac fibrosis significantly 
reduces, which can be due to the release of anti-
collagen agents by induced cardiomyocytes, or 
because of reduced secretions of fibroblast cells 
that had not completely reprogrammed, or 
perhaps both of them. 
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Cardiomyocytes are not the only cardiac 
cells that are needed, but also conductive cells 
that are damaged, or their amount and 
location is abnormal. Kapoor et al. showed that 
the Tbx18 transcription factor present in the 
cardiomyocytes cells culture media converted 
these cells into pulse producing cells. This 
experiment was done in vivo on guinea pig 
model of bradycardia, which returned heart 
rate to the normal state.56 It should be noted that 
more knowledge is needed on the expression of 
genes in different cells of the cardiac tissue to be 
capable of converting existing intact cell to 
desired cell in vivo; but with increasing 
knowledge of this process, in vivo 
reprogramming is not very far from minds. 
In vivo reprogramming in neural tissue  
Recently, in vivo tissue reprogramming of 
neural tissue has attracted the attention of 
scientific community. The first symposium on 
in vivo reprogramming was held in 2014 at the 
annual meeting of the Neuroscience 
Association in Washington, DC, which showed 
the attention of researchers in neuroscience to 
this research and therapeutic approach.57  
Cardiac tissue has a poor restorative 
potential, but in some regions such as sub-
ventricular zone and dentate gyrus, as well as 
certain areas of amygdala, there is an intrinsic 
potential to produce new cells.58,59 These newly 
generated cells can repair minor damages to 
the tissue.60 This reparative potential can be 
used to make it easier to convert neural cells 
with only one or two transcription factors. In 
the neural tissue, just like the cardiac tissue, 
there are cells that are some supportive cells, 
which they collectively called glia. These cells 
have some features of precursor cells.61  
Researchers in the field of in-vivo 
reprogramming whom focused on neural 
tissue repair have focused on these cells for 
conversion purposes. The first attempts on in-
vivo reprogramming of neural tissue were 
done to convert the evolutionary close cells. In 
a study by De la Rossa et al., in vivo 
reprogramming of cells from one layer of the 
cerebellum to the another layer cell was 
carried out by the Fezf2 transcription factor in 
the mouse embryo.62 Similar studies have been 
carried out by other researchers to convert cells 
of other layers of the fetal brain.63 It should be 
noted that the conversion of adult neurons to 
each other in the early stages of embryonic life 
is much simpler, and this is more complicated 
in adults. Another study was carried out to 
convert astrocytes to primary neurons by Niu 
et al., whose aim was to transform glial cells to 
functional neurons in the brain using a 
transcription factor called Sox2.15  
Researchers in this field,64-66 including 
Dehghan et al.,64 along with the factors of 
transcription, have paid attention on growth 
factors such as brain-derived neurotrophic 
factor (BDNF), fibroblast growth factor (FGF), 
and Noggin, as well as small molecules such as 
valproic acid. The newly generated cells from 
these studies integrate into brain circuits, and 
they are electrically active. In a study by Su  
et al., they converted spinal cord astrocytes to 
interneurons on the injury site.19 These 
interneurons also were capable of integrating 
into local circuits, and were functionally active. 
It was also found that only Sox2, and then 
Ascl1, were sufficient for this conversion.67,68 
Effects of Sox2 on cell reprogramming is not 
limited to the conversion of glia to the 
neurons, but can also be useful in pericyte to 
neuron conversion.69 MicroRNAs (miRNAs) 
have also play a major role in the in-vivo 
reprogramming of glial cells to the neuron.70 For 
example, Ghasemi-Kasman et al. showed that 
using miRNAs, astrocytes could be converted to 
neuroblasts, and then to neurons.71  
Recently, many studies have been 
conducted to reprogram glial cells to the 
damaged neurons of various diseases such as 
Alzheimer's disease, multiple sclerosis (MS), 
etc. These studies suggest that it is possible to 
replace damaged cells with functional ones 
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which can integrate to the brain circuits using 
this approach.17,64,72 It can be concluded from 
these studies that using various factors and 
environmental conditions, as well as body needs, 
it is possible to produce special types of cells in 
the body via in vivo reprogramming process. 
Therapeutic potentials of in-vivo 
reprogramming 
Many researchers around the world have 
sought to use in vivo reprogramming strategy 
for diseases treatments. Efforts of Zhou et al.,12 
Niu et al.,15 Rezvani et al.,42 and Song et al.43 to 
treat pancreatic and hepatic diseases, by in 
vivo reprogramming method, are highly 
appreciated. Besides, efforts of Ma et al.,47 Song 
et al.,48 Ieda et al.,50 and Li et al.53 have been 
focused on treating cardiac diseased with this 
method. Guo et al. also looked after the 
capability of this approach in brain injury 
models. They sought to convert the reactive 
astrocytes, which accumulated in the region 
after the onset of the damage or lesion, to the 
neurons in the adult mice brain.17 Dehghan et 
al. also looked for a way to replace the damaged 
oligodendrocytes with new ones in the animal 
models of MS.64 Applied efforts of neuroscience 
researchers in this area are discussed in detail in 
Li and Chen review article.61 
Challenges ahead for in-vivo 
reprogramming 
In-vivo reprogramming is a novel way of 
treating diseases. This method can replace new 
cells in the damaged tissue without the need for 
cell transplantation. Obviously, cell 
transplantation is complex and relatively 
invasive. Although the ability of this method to 
produce new cells in the body has been well 
documented in the studies described above, but 
there are many challenges ahead of this method 
to prove its ability to treat human diseases. 
However, human knowledge is growing, 
and new emerging technologies will be 
available to solve these problems and 
challenges. Researchers now reprogram the 
cells by artificial increasing in the expression of 
a number of transcription factors, but their 
works are still blinded, and they have little 
knowledge. With the advancement of 
genomics and proteomics, and in general 
genomics knowledge, it was hoped to achieve 
more specific, higher-performing transforming 
factors. Now, we know that by altering the 
epigenetic state of the cells, we are able to 
remove possible obstacles of reprogramming.73  
However, with the development of 
epigenetic knowledge, it is possible to find 
some drugs that will be capable of cell 
reprogramming, without the induction of gene 
expression. Of course, new technologies of 
gene editing such as clustered regularly 
interspaced short palindromic repeats 
(CRISPRs) are also powerful tools for cell 
reprogramming. Technologies of single cell 
manipulation that asses the genetic material 
and proteins of a cell individually, including 
single cell gene sequencing and single cell RNA 
sequencing, can also be effective in completing 
our knowledge. These new techniques 
introduce us the general conditions of the cells, 
so that we can come up with suitable strategies 
for converting cells. We know that the cells in 
the tissue are susceptible to conversion, but 
conditions such as cell death and the conversion 
to the unwanted types of cells are factors that 
decrease the efficacy of this method.74,75 
Therefore, we should look for ways to increase 
the efficiency of cell reprogramming.  
According to the above, it is clear that with 
the advancement of stem cell science and 
technology we can gain a clearer understanding 
of these cells and the processes occurring 
during cell reprogramming, and develop the 
technology of internal re-programming with a 
brighter and more open view. 
Another major obstacle to the development 
of in-vivo reprogramming is delivering 
pathways of compounds and factors. 
Reprogramming compounds must be delivered 
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safely, effectively, and optimized. Viral and 
plasmid vectors are the usual methods, but due 
to their disadvantages, they are not still ready 
human treatment applications.76,77 Although it 
is possible to deliver the reprogramming factors 
to the actual locations of damage, but their risk 
is still very high. On the other hand, 
transcription factors should be expressed to a 
large extent, whose effects and consequences 
are still unclear. Given the limitations of genetic 
reprogramming, today, chemical 
reprogramming using small molecule 
compounds has received attention. In this 
method, although the need for high expression 
of transcription factors has been almost 
eliminated, still some obstacles remained. 
Delivering the compounds to the site of lesion, 
and maintaining their therapeutic 
concentrations over a long period of time are 
the major problems. It's worth noting, however, 
that nanotechnology has opened up new door 
to overcome these problems. Another hope is 
also injecting high concentrations of mRNAs to 
the damaged tissue to transiently increase the 
expression of desired genes. 
After all, the safety and effectiveness of this 
method should be tested in animal models 
evolutionary close to humans including 
monkeys. These tests help us to test the quality 
of this method in human-size animals. 
With the advancements of in-vivo 
programming technology, gradually more 
efficient methods of reprogramming and 
targeting will be developed. These methods 
should all receive the necessary approvals 
from the relevant organizations, but 
nevertheless the need for this technology will 
make the verification processes move faster. Of 
course, for patients who are disappointed with 
other therapies, it is possible to use in vivo 
reprogramming more quickly. 
Conclusion 
At the end, in short, in vivo reprogramming 
technology is a regenerative medicine 
therapeutic method based on developmental 
biology and cell reprogramming. Recently, 
many studies have been published on chronic 
diseases associated with pancreatic, cardiac, 
and neural tissues of small laboratory animals 
that have reported promising results. Despite 
all the positive aspects of this method, there 
are still challenges facing this new technology, 
which we hope they would be solved 
gradually. With the gradual removal of 
obstacles and challenges, the use of this 
method for medical purposes is not far from 
mind. We hope that this technology will 
progress as quickly as possible, and we will 
soon see chronic and nonchronic diseases 
patients treated with this approach. 
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